531 related articles for article (PubMed ID: 9819046)
21. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
[TBL] [Abstract][Full Text] [Related]
22. Levels of prothrombin activation peptide F1+2 in patients with a bleeding tendency.
Ingerslev J; Holm M; Christiansen K; Knudsen L; Négrier C
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S129-34. PubMed ID: 9819044
[TBL] [Abstract][Full Text] [Related]
23. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.
Hedner U
Thromb Haemost; 2008 Oct; 100(4):557-62. PubMed ID: 18841276
[TBL] [Abstract][Full Text] [Related]
24. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
25. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
Young G; Shafer FE; Rojas P; Seremetis S
Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
[TBL] [Abstract][Full Text] [Related]
26. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
[TBL] [Abstract][Full Text] [Related]
27. Successful control of central nervous system bleeding in two newborns with severe factor VII deficiency using rFVIIa administered via Port-a-Cath.
Karimi M
Semin Hematol; 2008 Apr; 45(2 Suppl 1):S74. PubMed ID: 18544432
[TBL] [Abstract][Full Text] [Related]
28. Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors.
Łaguna P; Mital A
Adv Clin Exp Med; 2012; 21(4):519-24. PubMed ID: 23240458
[TBL] [Abstract][Full Text] [Related]
29. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
Young G; Shapiro AD; Walsh CE; Gruppo RA; Gut RZ; Cooper DL
Haemophilia; 2012 May; 18(3):392-9. PubMed ID: 22171621
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of using recombinant factor VIIa in continuous infusion.
Schulman S; Bech Jensen M; Varon D; Keller N; Gitel S; Horoszowski H; Heim M; Martinowitz U
Thromb Haemost; 1996 Mar; 75(3):432-6. PubMed ID: 8701403
[TBL] [Abstract][Full Text] [Related]
31. [Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts].
Auerswald G; Muntean W; Kemkes-Matthes B; Klamroth R; Krause M; Kurnik K; Oldenburg J; Pabinger-Fasching I; Schramm W; Zimmermann R; Zotz RB
Hamostaseologie; 2009 May; 29(2):197-203. PubMed ID: 19404511
[TBL] [Abstract][Full Text] [Related]
32. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
33. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
[TBL] [Abstract][Full Text] [Related]
34. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
Lin PC; Liao YM; Tsai SP; Chang TT
Pediatr Blood Cancer; 2011 Dec; 57(6):1029-33. PubMed ID: 21793191
[TBL] [Abstract][Full Text] [Related]
35. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.
Dunkley S; Phillips L; McCall P; Brereton J; Lindeman R; Jankelowitz G; Cameron P
Ann Thorac Surg; 2008 Mar; 85(3):836-44. PubMed ID: 18291152
[TBL] [Abstract][Full Text] [Related]
36. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
Mathias M; Khair K; Hann I; Liesner R
Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
[TBL] [Abstract][Full Text] [Related]
37. Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE).
Gruppo RA; Kessler CM; Neufeld EJ; Cooper DL
Haemophilia; 2013 Jul; 19(4):524-32. PubMed ID: 23551918
[TBL] [Abstract][Full Text] [Related]
38. [Treatment and prevention of haemorrhage with recombinant activated factor VII, not only in hemophilia].
Levi M; Friederich PW; van der Meer J
Ned Tijdschr Geneeskd; 2002 Dec; 146(52):2534-7. PubMed ID: 12532665
[TBL] [Abstract][Full Text] [Related]
39. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
[TBL] [Abstract][Full Text] [Related]
40. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders.
Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S
Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
